Investor Presentaiton

Transaction Rationale: Strategically fills gaps for ACL and will generate more than $10m of operational efficiencies Scale in NSW ivivi Broader offerings Medlab: 205 ACCs in NSW (9.8% of NSW ACCs) • . . . Combined ACL/Medlab doubles in scale to 20.4% of NSW ACCS Provides scale to invest in further efficiencies via larger consolidated laboratory Complementary footprint Increased drive through sites (COVID-19 traveller opportunity) ACL can insource majority of Medlab's testing being sent away to other providers Increased ability to invest in digital histopathology Medlab is AS4308 accredited: provides ACL with the ability to compete in NSW and nationally for commercial drug and alcohol testing tenders Excellent Entry platform in Qld • • Medlab: 83 ACCs in Queensland (6.5% of ACCs in Qld) Allows full laboratory with scale Accelerated growth and scale for investment • Histology lab opportunities • Improved laboratory platform Business will be integrated to enable scale benefits to be achieved • Opportunity to combine labs into one highly automated central lab in NSW - location TBD • The Queensland lab comprises 1,000m² of space and is on substantial land holding (~6,500m²) allowing for future expansion • Future-proof the business in both NSW and Queensland and provide strong growth platforms in both States Operational Synergies and Integration Track Record • Operational synergies estimated to be >$10m that can be realised over next 18 to 24 months Track record of integration success onto unified national pathology platform 5

View entire presentation